U.S. stocks are rising to trim their losses in what’s set to be one of their worst weeks of the year. The S&P 500 climbed 0.7 ...

Traders brace for volatility with a record $6.6 trillion in options due to expire in Friday’s ‘triple witching’ The Fed cut ...

In November, NVO shares crossed into a long-term bear market as they fell below their 20-month moving average - a key ...

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture Justice Kyra Harris Bolden ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

Although Novo underscored that patients in the trial achieved up to 22.7% of weight loss with CagriSema, analysts previously said they were hoping to see whether it would significantly beat Lilly’s ...

Novo Nordisk reported disappointing results from its trial on the obesity drug CagriSema, causing a significant drop in market value. The drug's weight-loss outcome was below expectations, affecting ...

Pedersen and Mariam Sunny LONDON/COPENHAGEN (Reuters) - Novo Nordisk shareholders were seeking on Friday to find out why such ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.